X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (32) 32
oncology (31) 31
humans (30) 30
female (27) 27
aged (23) 23
cancer (23) 23
middle aged (23) 23
adult (19) 19
tumors (17) 17
male (16) 16
sarcoma (16) 16
chemotherapy (13) 13
clinical trials (13) 13
hematology, oncology and palliative medicine (13) 13
care and treatment (12) 12
young adult (12) 12
disease-free survival (11) 11
aged, 80 and over (10) 10
treatment outcome (10) 10
france (9) 9
research (9) 9
analysis (8) 8
ovarian cancer (8) 8
adolescent (7) 7
antineoplastic agents - therapeutic use (7) 7
cancer therapies (7) 7
pathology (7) 7
patients (7) 7
soft-tissue sarcomas (7) 7
survival (7) 7
diagnosis (6) 6
neoplasm staging (6) 6
research article (6) 6
risk factors (6) 6
solid tumors (6) 6
studies (6) 6
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
bevacizumab (5) 5
carcinoma (5) 5
management (5) 5
medical research (5) 5
mutation (5) 5
obstetrics & gynecology (5) 5
ovarian neoplasms - drug therapy (5) 5
population (5) 5
prospective studies (5) 5
radiation therapy (5) 5
sarcoma - pathology (5) 5
antineoplastic agents - administration & dosage (4) 4
antineoplastic agents - adverse effects (4) 4
cancer research (4) 4
disease progression (4) 4
double-blind method (4) 4
drug administration schedule (4) 4
epidemiology (4) 4
health aspects (4) 4
health risk assessment (4) 4
hospitals (4) 4
life sciences (4) 4
medicine (4) 4
medicine, experimental (4) 4
metastasis (4) 4
ovarian neoplasms - pathology (4) 4
pazopanib (4) 4
prognosis (4) 4
recommendations (4) 4
sarcoma - diagnosis (4) 4
soft tissue neoplasms - pathology (4) 4
time factors (4) 4
age (3) 3
angiogenesis (3) 3
antimitotic agents (3) 3
antineoplastic agents (3) 3
bone cancer (3) 3
carboplatin (3) 3
child (3) 3
combined modality therapy (3) 3
consensus (3) 3
double-blind (3) 3
follow-up studies (3) 3
genetics (3) 3
histology (3) 3
infusions, intravenous (3) 3
kaplan-meier estimate (3) 3
liposarcoma (3) 3
maintenance therapy (3) 3
medical oncology (3) 3
medical prognosis (3) 3
multidisciplinary sciences (3) 3
neoadjuvant chemotherapy (3) 3
neoplasm recurrence, local (3) 3
neoplasm recurrence, local - drug therapy (3) 3
neoplasms. tumors. oncology. including cancer and carcinogens (3) 3
osteosarcoma (3) 3
paclitaxel (3) 3
paclitaxel - administration & dosage (3) 3
peritoneal neoplasms - pathology (3) 3
practice guidelines as topic (3) 3
protein kinase inhibitors - adverse effects (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 8, pp. 799 - 808
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 12, pp. 1732 - 1742
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 10, pp. 942 - 949
Journal Article
Lancet, The, ISSN 0140-6736, 2009, Volume 373, Issue 9674, pp. 1532 - 1542
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 11, pp. 1045 - 1052
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 1, pp. 75 - 87
Summary Background Poly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian carcinomas with homologous recombination deficiency. Along with BRCA1... 
Hematology, Oncology and Palliative Medicine | POLY(ADP-RIBOSE) POLYMERASE | OLAPARIB | ONCOLOGY | HOMOLOGOUS RECOMBINATION DEFICIENCY | MUTANT-CELLS | DNA-REPAIR | CANCER | HETEROZYGOSITY | TUMORS | BREAST | GENOMIC LOSS | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Germ-Line Mutation - genetics | Neoplasm Recurrence, Local - pathology | Ovarian Neoplasms - genetics | Neoplasms, Glandular and Epithelial - genetics | Peritoneal Neoplasms - drug therapy | Fallopian Tube Neoplasms - genetics | Female | Antineoplastic Agents - pharmacology | Poly(ADP-ribose) Polymerases - chemistry | Ovarian Neoplasms - drug therapy | Platinum - pharmacology | Fallopian Tube Neoplasms - drug therapy | Peritoneal Neoplasms - pathology | Neoplasms, Glandular and Epithelial - pathology | Fallopian Tube Neoplasms - pathology | Survival Rate | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | BRCA1 Protein - genetics | International Agencies | Peritoneal Neoplasms - genetics | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Indoles - therapeutic use | Neoplasm Recurrence, Local - genetics | Aged | Neoplasm Staging | BRCA2 Protein - genetics | Drug Resistance, Neoplasm - drug effects | Sugars | Monosaccharides | Ovarian cancer | Analysis | Carcinoma | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 78 - 89
Summary Background Angiogenesis is a target in the treatment of ovarian cancer. Nintedanib, an oral triple angiokinase inhibitor of VEGF receptor,... 
Hematology, Oncology and Palliative Medicine | BIBF 1120 | DES CANCERS | INTERGROUP TRIAL | LABEL DOSE-ESCALATION | CISPLATIN | ONCOLOGY | BEVACIZUMAB | TRIPLE ANGIOKINASE INHIBITOR | CARBOPLATIN PLUS PACLITAXEL | III TRIAL | MAINTENANCE THERAPY | Humans | Middle Aged | Ovarian Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Response Evaluation Criteria in Solid Tumors | Diarrhea - chemically induced | Cytoreduction Surgical Procedures | Indoles - administration & dosage | Young Adult | Peritoneal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Carcinoma - pathology | Neutropenia - chemically induced | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Carcinoma - drug therapy | Peritoneal Neoplasms - pathology | Double-Blind Method | Carcinoma - surgery | Peritoneal Neoplasms - surgery | Anemia - chemically induced | Carboplatin - administration & dosage | Fallopian Tube Neoplasms - pathology | Thrombocytopenia - chemically induced | Disease Progression | Disease-Free Survival | Indoles - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Fallopian Tube Neoplasms - surgery | Intention to Treat Analysis | Aged | Neoplasm Staging | Ovarian Neoplasms - surgery | Clinical trials | Chemotherapy | Hospitals | Growth factors | Cancer | Ovarian cancer | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 3, pp. 312 - 319
Journal Article